Filling the gap: Taking care of social and medical needs enhances diabetes care and results.

Published Date: 05 Apr 2023

Almost one in five adults in America has diabetes. The common condition is not, however, easy to manage or treat. The No. 1 cause of death worldwide is diabetes and its complications. One of the main causes of lower-limb and adult blindness.

Read Full News

Latest News



Todays Updates


Early PET May Help Tailor Therapy in Hodgkin Lymphoma


A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

When Healthcare Chatbots Fall Short of Human Connection


Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC


Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.

PRO Data Strengthen Case for Dato-DXd in First-Line TNBC


Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.

FDA Advisors Split on Regimens for Breast, Prostate Cancers


The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.

Combo Therapy Boosts Early CML Response but Not Long Term


A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

De-escalation Misses the Mark in Inflammatory Breast Cancer


Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.

Todays Updates


Early PET May Help Tailor Therapy in Hodgkin Lymphoma


A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

When Healthcare Chatbots Fall Short of Human Connection


Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC


Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.

PRO Data Strengthen Case for Dato-DXd in First-Line TNBC


Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.

FDA Advisors Split on Regimens for Breast, Prostate Cancers


The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.

Combo Therapy Boosts Early CML Response but Not Long Term


A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

De-escalation Misses the Mark in Inflammatory Breast Cancer


Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.

2.

Video: Liver transplant for patients with advanced colorectal cancer

3.

New guidelines for radiation therapy for HPV-associated head and neck cancer

4.

Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer

5.

AI Model Has Promise for Predicting Checkpoint Inhibitor Activity in NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot